Literature DB >> 26536207

Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators.

Jacques Donnez1, Pablo Arriagada, Olivier Donnez, Marie-Madeleine Dolmans.   

Abstract

PURPOSE OF REVIEW: To review the current management of myomas with the advent of selective progesterone receptor modulators. RECENT
FINDINGS: Selective progesterone receptor modulators have proved effective and recent publications on the use of ulipristal acetate (UPA) have analyzed the performance of long-term intermittent utilization of 10 mg UPA given in repeated courses of 3 months. This long-term intermittent therapy maximizes the efficacy of UPA. Indeed, control of bleeding is achieved sooner after each course. With each subsequent course, a statistically greater number of patients show a fibroid volume reduction of more than 50%.
SUMMARY: The choice of therapy is influenced by different factors, such as the severity of symptoms, tumor characteristics, age, and wish to preserve the uterus (and fertility). Use of UPA will undoubtedly modify the surgical approach.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26536207     DOI: 10.1097/GCO.0000000000000229

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  12 in total

Review 1.  Endocrine-disrupting chemicals and uterine fibroids.

Authors:  Tiffany A Katz; Qiwei Yang; Lindsey S Treviño; Cheryl Lyn Walker; Ayman Al-Hendy
Journal:  Fertil Steril       Date:  2016-08-21       Impact factor: 7.329

Review 2.  Heavy menstrual bleeding diagnosis and medical management.

Authors:  Intira Sriprasert; Tarita Pakrashi; Thomas Kimble; David F Archer
Journal:  Contracept Reprod Med       Date:  2017-07-24

Review 3.  Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.

Authors:  Thomas Rabe; Nicole Saenger; Andreas D Ebert; Thomas Roemer; Hans-Rudolf Tinneberg; Rudy Leon De Wilde; Markus Wallwiener
Journal:  Biomed Res Int       Date:  2018-06-24       Impact factor: 3.411

4.  Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.

Authors:  Iwona Szydłowska; Aleksandra Marciniak; Jolanta Nawrocka-Rutkowska; Aleksandra Rył; Andrzej Starczewski
Journal:  Int J Environ Res Public Health       Date:  2020-01-28       Impact factor: 3.390

Review 5.  Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Authors:  Mohamed Ali; Sara A R; Ayman Al Hendy
Journal:  Expert Rev Clin Pharmacol       Date:  2021-03-15       Impact factor: 5.045

Review 6.  Long-term intermittent pharmacological therapy of uterine fibroids - a possibility to avoid hysterectomy and its negative consequences.

Authors:  Anita Olejek; Katarzyna Olszak-Wąsik; Anna Czerwinska-Bednarska
Journal:  Prz Menopauzalny       Date:  2016-03-29

Review 7.  Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review.

Authors:  Michał Ciebiera; Krzysztof Łukaszuk; Błażej Męczekalski; Magdalena Ciebiera; Cezary Wojtyła; Aneta Słabuszewska-Jóźwiak; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2017-12-01       Impact factor: 5.923

Review 8.  Uterine fibroid management: from the present to the future.

Authors:  Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Hum Reprod Update       Date:  2016-07-27       Impact factor: 15.610

Review 9.  Ulipristal acetate as a treatment option for uterine fibroids.

Authors:  Karolina Piecak; Paweł Milart; Ewa Woźniakowska; Tomasz Paszkowski
Journal:  Prz Menopauzalny       Date:  2017-12-30

Review 10.  Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.

Authors:  Mohamed Ali; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2017-09-01       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.